Colombat P, Gorin N C, Lemonnier M P, Binet C, Laporte J P, Douay L, Desbois I, Lopez M, Lamagnere J P, Najman A
Service d'Oncologie Médicale et Maladies du Sang CHU Bretonneau, Tours, France.
J Clin Oncol. 1990 Apr;8(4):630-7. doi: 10.1200/JCO.1990.8.4.630.
Forty-six patients with non-Hodgkin's lymphoma (NHL) were treated with autologous bone marrow transplantation (ABMT) in two different institutions. All patients were pretreated with conventional chemotherapy. Three different conditioning regimens were used, and 20 patients underwent bone marrow purging. Twelve patients were treated in first complete remission (CR); eight are in unmaintained CR 8 to 104 months after ABMT. Five patients were grafted in first partial remission (PR) after conventional therapy; all achieved CR, and all remain in prolonged CR (first CR for four patients, second CR for one patient). Of 21 patients with chemosensitive relapses, 13 patients are in prolonged unmaintained CR 8 to 94 months after ABMT. Eight patients with resistant disease remained uncured by ABMT; all eight died, six from progressive illness and two from toxicity. The current 3-year disease-free probability is 60% for all patients, 0% for refractory disease; 82% for first PR or CR, and 60% for sensitive relapses (SRs). These results confirm the efficacy of ABMT in the treatment of chemosensitive NHL with bad prognosis.
46例非霍奇金淋巴瘤（NHL）患者在两家不同机构接受了自体骨髓移植（ABMT）治疗。所有患者均接受了传统化疗预处理。采用了三种不同的预处理方案，20例患者进行了骨髓净化。12例患者在首次完全缓解（CR）时接受治疗；8例在ABMT后8至104个月处于未维持的CR状态。5例患者在传统治疗后首次部分缓解（PR）时接受移植；均实现CR，且均处于长期CR状态（4例为首次CR，1例为第二次CR）。在21例化疗敏感复发患者中，13例在ABMT后8至94个月处于长期未维持的CR状态。8例耐药疾病患者未通过ABMT治愈；8例均死亡，6例死于疾病进展，2例死于毒性反应。目前所有患者的3年无病概率为60%，难治性疾病为0%；首次PR或CR为82%，敏感复发（SR）为60%。这些结果证实了ABMT在治疗预后不良的化疗敏感NHL中的疗效。
